FDA approves Orca Bio's Tregzi T-cell therapy
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA on Tuesday approved Tregzi, a personalized T-cell therapy from Orca Bio designed to reduce the risk of graft-versus-host disease in blood cancer patients undergoing stem cell transplants.
- Tregzi serves as an alternative to traditional matched-donor stem cell transplantation, which can cure certain blood cancers but carries a high risk of chronic graft-versus-host disease and other long-term complications.
- Orca Bio, a private biotech company, developed Tregzi with the goal of eliminating the trade-off between curative potential and the immune complications of conventional transplants.
- Nate Fernhoff, Orca's CEO, said Tregzi's approval represents a way to improve survival free from graft-versus-host disease, calling it "a really important option for leukemia patients."
- The therapy is positioned for leukemia patients specifically, targeting those whose only curative path historically required accepting graft-versus-host disease risk as part of treatment.
Why it matters: For blood cancer patients facing stem cell transplants, chronic graft-versus-host disease has been an accepted trade-off for a cure — Tregzi's approval gives them a personalized T-cell option that the company explicitly frames as breaking that trade-off. Orca Bio, a private biotech, now has its first FDA-approved product targeting a population with few alternatives.
Ask SkimNews
